POCI PRECISION OPTICS CORPORATION, INC.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 867840 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY53.0%
TTM net income YoY59.6%
TTM EPS YoY69.4%
Revenue 3-yr CAGR17.6%
Net income 3-yr CAGR—
Margins
Gross margin19.2%
Operating margin-7.4%
Net margin-7.5%
FCF margin—
EBITDA margin-6.5%
Returns
ROE-15.9%
ROA-9.3%
ROIC (approx.)-16.3%
Asset turnover1.25x
Leverage & solvency
Liabilities / assets34.0%
Debt / equity0.06x
Current ratio2.46x
Interest coverage-17.82x
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-0.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | $31.53M | $19.09M |
| Cost of revenue | $26.10M | $15.69M |
| Gross profit | $5.43M | $3.40M |
| R&D expense | $1.03M | $1.16M |
| SG&A expense | $7.91M | $7.80M |
| Operating income | -$3.51M | -$5.55M |
| Interest expense | $148,129 | $227,019 |
| Pretax income | -$3.62M | -$5.78M |
| Income tax | $4,958 | $1,936 |
| Net income | -$3.63M | -$5.78M |
| EBITDA | -$3.23M | -$5.34M |
| EPS (basic) | -0.43 | -0.85 |
| EPS (diluted) | -0.43 | -0.85 |
| Weighted avg. shares (diluted) | 8.53M | 6.79M |
| Balance sheet | ||
| Cash & equivalents | $9.84M | $1.77M |
| Receivables | $5.94M | $4.34M |
| Inventory | $3.83M | $3.56M |
| Current assets | $20.11M | $10.06M |
| PP&E, net | $887,713 | $533,792 |
| Goodwill | $8.82M | $8.82M |
| Intangibles | $212,889 | $232,493 |
| Total assets | $32.34M | $19.79M |
| Current liabilities | $8.83M | $6.15M |
| Short-term debt | $577,898 | $577,898 |
| Long-term debt | $711,305 | $1.29M |
| Total debt | $1.29M | $1.87M |
| Total liabilities | $11.99M | $7.53M |
| Shareholders' equity | $20.35M | $12.26M |
| Net debt | -$8.55M | $93,368 |
| Shares outstanding | 10.97M | 7.71M |
| Cash flow statement | ||
| Operating cash flow | -$1.55M | -$3.40M |
| Capital expenditure | $426,786 | $227,209 |
| Free cash flow | -$1.98M | -$3.62M |
| Investing cash flow | -$429,350 | -$233,473 |
| Financing cash flow | $10.05M | $5.00M |
| Depreciation & amortization | $279,277 | $212,439 |
| Stock-based compensation | $1.14M | $1.61M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.